Scientists have discovered genetic variants that help explain why weight-loss drugs such as Wegovy and Mounjaro work dramatically better for some people than others, according to a study in the journal Nature. A examination involving 15,000 people taking these medications found that those carrying specific gene variations experienced substantially greater weight loss over roughly approximately eight months of treatment. Whilst participants lost roughly 11.7 per cent of their body weight, some shed as much as 30 per cent whilst others noticed little difference. The findings could also help explain why certain individuals suffer severe adverse effects including nausea and vomiting. Experts suggest the genetic factors, though limited in their impact, work alongside other elements such as age, sex and ethnic background to influence how well these widely-used obesity treatments perform.
The genetic breakthrough revolutionising obesity treatment
Researchers analysing data from 23andMe discovered two key genetic variants that substantially affect how well weight-loss medications work. The first variant, linked to appetite regulation and digestion, is associated with greater weight loss when taking drugs like Wegovy and Mounjaro. People carrying a single copy of this variant lose approximately 0.76 kilogrammes on average more, whilst those with two copies can double that additional weight loss. The variant is particularly common among people of European ancestry, with 64 per cent carrying one copy and 16 per cent carrying two, compared to just 7 per cent of African Americans.
The other genetic variant identified in the study is associated with significant GI side-effects when using tirzepatide, the key component in Mounjaro. Researchers found that roughly 1 per cent of people with this variant experience exceptionally severe vomiting—nearly 15 times more severe than common adverse effects. Professor Ruth Loos from the University of Copenhagen, who discussed the research, emphasised that whilst the genetic effects are fairly modest, they are similar to other influential factors and should not be overlooked as insignificant in understanding individual drug responses.
- Genetic variants influence weight loss by around 0.76 kilogrammes per person
- European ancestry populations show greater frequency of weight-loss associated genes
- Second genetic variant elevates risk of severe nausea and vomiting
- Genetic factors operate in conjunction with age, sex and ethnicity in determining effectiveness
How genes affect drug response
The weight loss variant outlined
The primary genetic variant discovered in the research influences the body’s appetite regulation and metabolic function, substantially influencing how weight-loss medications perform. Individuals possessing this variant show enhanced weight loss when taking drugs such as Wegovy and Mounjaro, with studies suggesting an additional 0.76 kilogrammes reduced on average versus those without the variant. The mechanism appears connected to how the genes interact with the medications’ appetite-suppressing properties, enhancing their effectiveness in decreasing appetite and promoting satiety during treatment.
The effect becomes even more significant for those possessing two copies of the genetic variant. These individuals can effectively increase their additional weight loss, possibly achieving significant advantages over those with one copy when pursuing weight management therapy. This genetic doubling effect amounts to a substantial difference in outcomes, especially valuable for individuals seeking optimal treatment outcomes. However, researchers stress that this hereditary benefit comes with a trade-off, as carriers also suffer heightened GI side-effects, including sickness and vomiting during treatment.
Heritage and genetic variation
The frequency of this weight-loss-related genetic variant shows considerable variation across different populations, with ancestry playing a determining role in likelihood of inheritance. European ancestry populations exhibit markedly greater carrier rates compared to other ethnic groups, reflecting genetic diversity across global populations. This disparity carries significant implications for tailored medical approaches and clarifying why weight-loss drug efficacy may be different across individuals from different ethnic backgrounds, thereby impacting treatment planning and outcome expectations.
| Population Group | Percentage Carrying Gene Variant |
|---|---|
| European ancestry (one copy) | 64% |
| European ancestry (two copies) | 16% |
| African American (one copy) | 7% |
| African American (two copies) | Data not specified |
Understanding these hereditary patterns helps explain observed variations in drug response across diverse groups. The significantly higher occurrence of the weight-reduction variant among people of European descent suggests they may experience greater advantages from these drugs on average. Conversely, reduced carrier frequencies in African American communities indicate distinct genetic patterns that may require different treatment approaches or adjusted expectations regarding weight-reduction results with current obesity medications.
Beyond genetics: the broader context
Whilst inherited differences provide valuable insights into individual drug responses, researchers emphasise that genetic elements represent only one piece of a much bigger puzzle. Professor Ruth Loos notes that the hereditary influence, though limited, stays “similar to other factors – and not trivial.” This indicates that numerous additional variables affect how effectively weight-loss medications function for each person. Gender, age, daily habits, metabolic rate and overall health status all play a significant role to results from treatment, sometimes overshadowing genetic predisposition entirely.
The multifaceted nature of personalised medicine is highlighted when considering that 15,000 trial participants experienced widely varying weight loss despite receiving identical pharmaceutical treatments. Some shed 30 per cent of their total weight across eight months, whilst others experienced minimal loss. This striking difference underscores that genetic factors by themselves cannot predict favourable results. Lifestyle elements, compliance with treatment regimens, eating patterns and individual physiology work together with genetic code to establish end results, indicating that a tailored method to weight management is crucial.
- Sex differences may affect drug metabolism and weight loss outcomes considerably
- Age affects metabolic rate and medication effectiveness in measurable ways
- Ethnic background shapes both genetic factors and environmental health influences
- Lifestyle choices and diet stay essential despite genetic predisposition
- Individual health conditions influence medication responses unpredictably
Sex, age and ethnic considerations
Sex differences are important factors in shaping how weight-loss medications impact individuals, with emerging evidence suggesting men and women might have varying responses to drugs like Wegovy and Mounjaro. Hormonal differences, distinct body composition patterns and different metabolic rates between sexes could impact drug uptake and efficacy. Age similarly impacts treatment success, as senior patients usually display slower rates of metabolism and could undergo different medication breakdown compared to younger people, potentially affecting weight loss patterns and side-effect severity.
Ethnicity encompasses both genetic and socioeconomic dimensions that influence medication outcomes beyond straightforward hereditary factors. Cultural dietary patterns, access to healthcare, the affordability of medications and lifestyle factors vary significantly across ethnic groups, all impacting weight-loss drug efficacy. Researchers accept that comprehending these overlapping factors demands thorough examination beyond genetic analysis alone, guaranteeing that future treatment guidelines address the needs of diverse populations equitably and efficiently.
From laboratory findings to clinical application
The identification of genetic variations influencing weight-loss drug efficacy creates exciting opportunities for tailored medical treatment in weight management. Translating these research results into clinical practice requires careful consideration of how genetic screening could be incorporated within NHS prescription guidelines and private medical pathways. Healthcare professionals may in future use genetic testing to determine which patients will respond most favourably to particular drugs, possibly enhancing clinical results and minimising unwanted adverse effects. However, implementing such screening at scale presents logistical and financial obstacles that the NHS must address systematically.
Current obesity treatment continues to be largely one-size-fits-all, with patients receiving identical medications irrespective of their genetic makeup. As genetic understanding deepens, clinicians could customise medication regimens to individual genetic profiles, maximising weight loss whilst minimising adverse reactions. This shift towards precision medicine requires funding in genetic testing infrastructure, clinician education programmes and revised treatment protocols. The research suggests that whilst genetic factors play a modest role, their identification combined with assessment of other variables could significantly enhance treatment efficacy and client outcomes across diverse populations.
The precision medicine promise
Precision medicine marks a fundamental shift from conventional treatment guidelines towards individualised healthcare strategies based on genetic and physical traits. By identifying which patients carry beneficial genetic variants, clinicians could improve drug choice and treatment dosages, thereby enhancing weight loss outcomes whilst reducing sickness and vomiting issues. This approach promises more efficient resource use, enhanced patient satisfaction and greater assurance in obesity management across the NHS and private healthcare providers.
- Genetic screening could determine how individual patients respond to drugs precisely
- Personalised dosing regimens may minimise harmful side effects significantly
- Precision approaches optimise treatment satisfaction and clinical outcomes significantly
What this means for service users today
For the vast numbers of people currently taking weight-loss medications like Wegovy and Mounjaro, these genetic discoveries offer significant information into why their results differ so dramatically. Whilst hereditary elements represent only a limited effect on drug effectiveness, they work together with other significant variables including sex, age and cultural origin to shape specific responses. Understanding these trends helps account for why some patients experience significant weight losses of 30 per cent or more, whilst others see little benefit despite taking identical medications. This knowledge supports the disappointment patients widely experience when treatments fail to deliver expected benefits, suggesting physiological elements rather than lack of effort play a key part.
At present, the NHS and independent healthcare providers dispense weight-loss drugs without genetic testing, which means patients receive uniform care irrespective of their individual genetic profile. The majority of individuals taking these medications are often unaware whether they have genetic variants that might indicate their reaction or susceptibility to side-effects like intense nausea. Whilst genetic screening is not currently widely available through the health service, this research provides a foundation for future bespoke treatment methods. Patients discussing treatment options with healthcare providers can now recognise that their genetic makeup may influence outcomes, potentially encouraging more meaningful discussions about practical expectations and personal risk considerations before beginning medication.